-
公开(公告)号:EP4029877A1
公开(公告)日:2022-07-20
申请号:EP21217086.4
申请日:2018-08-03
申请人: Amgen, Inc
发明人: ALI, Khaled, M.K.Z. , AGRAWAL, Neeraj, Jagdish , KANNAN, Gunasekaran , FOLTZ, Ian , WANG, Zhulun , BATES, Daren , MOCK, Marissa , TAKENAKA, Shunseke
摘要: Provided herein are IL-21 muteins and fusion proteins comprising the same for use in methods of treating a disease. Related conjugates, nucleic acids, vectors, host cells, pharmaceutical compositions and kits are also provided herein. Methods of making the IL-21 muteins and fusion proteins comprising the same, as well as methods of treating a subject in need thereof, are provided by the present disclosure. Further provided are PD-1 antigen-binding proteins.
-
公开(公告)号:EP3737694A1
公开(公告)日:2020-11-18
申请号:EP19703451.5
申请日:2019-01-11
申请人: Amgen Inc.
-
公开(公告)号:EP4067493A1
公开(公告)日:2022-10-05
申请号:EP22159835.2
申请日:2017-05-11
申请人: Amgen Inc.
摘要: This invention relates to the general field of recombinant expression of polypeptides in animal cell culture. More specifically, the invention concerns improved selection of cells transfected with recombinantly engineered vectors designed to express polypeptides, in particular heteromultimeric polypeptides.
-
-